Biotechnology company GlycoMimetics Inc (Nasdaq:GLYC) said on Tuesday that Apollomics has dosed the first patient in China in a Phase 3 clinical trial of GlycoMimetics' APL-106 for the treatment of adults with relapsed or refractory acute myeloid leukemia (AML).

Discovered and developed by GlycoMimetics, uproleselan is an investigational, first-in-class, targeted inhibitor of E-selectin. Uproleselan is designed to block E-selectin (an adhesion molecule on cells in the bone marrow) from binding with blood cancer cells as a targeted approach to disrupting well-established mechanisms of leukemic cell resistance within the bone marrow microenvironment.

Apollomics' Phase 3 trial with APL-106 (uproleselan injection) is part of the overall development programme in China, which includes an ongoing Phase 1 pharmacokinetics (PK) and tolerability study.

The Phase 3 clinical trial is part of a randomized, double-blind, placebo controlled, bridging study programme that will evaluate the efficacy of uproleselan in combination with chemotherapy, compared to chemotherapy alone, for treating relapsed/refractory AML.

In addition, the trial will enroll approximately 140 adult patients with primary refractory AML or relapsed AML and eligible to receive induction chemotherapy. The primary endpoint for the Apollomics Phase 3 trial is overall survival, concluded the companies.